GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Price-to-Tangible-Book

RayzeBio (RayzeBio) Price-to-Tangible-Book : 6.50 (As of Jun. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Price-to-Tangible-Book?

As of today (2024-06-11), RayzeBio's share price is $62.49. RayzeBio's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was $9.62. Hence, RayzeBio's Price to Tangible Book Ratio of today is 6.50.

The historical rank and industry rank for RayzeBio's Price-to-Tangible-Book or its related term are showing as below:

RYZB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31   Med: 2.31   Max: 6.5
Current: 6.5

During the past 3 years, RayzeBio's highest Price to Tangible Book Ratio was 6.50. The lowest was 2.31. And the median was 2.31.

RYZB's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.79 vs RYZB: 6.50

A closely related ratio is called PB Ratio. As of today, RayzeBio's share price is $62.49. RayzeBio's Book Value per Sharefor the quarter that ended in Sep. 2023 was $9.62. Hence, RayzeBio's P/B Ratio of today is 6.50.


RayzeBio Price-to-Tangible-Book Historical Data

The historical data trend for RayzeBio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Price-to-Tangible-Book Chart

RayzeBio Annual Data
Trend Dec20 Dec21 Dec22
Price-to-Tangible-Book
- - -

RayzeBio Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23
Price-to-Tangible-Book Get a 7-Day Free Trial - - - - 2.31

Competitive Comparison of RayzeBio's Price-to-Tangible-Book

For the Biotechnology subindustry, RayzeBio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RayzeBio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where RayzeBio's Price-to-Tangible-Book falls into.



RayzeBio Price-to-Tangible-Book Calculation

RayzeBio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2023 )
=62.49/9.617
=6.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


RayzeBio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of RayzeBio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


RayzeBio (RayzeBio) Business Description

Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121
RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.
Executives
Hauwermeiren Timothy Van director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi director SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush officer: Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p. 10 percent owner 280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song director, officer: President and Chief Executive C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran officer: Chief Medical Officer 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p. 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129